Key Points- FDA review advances: PolyPid's NDA for D-PLEX100 was accepted on July 27, 2026, with priority review and a Nov. 28 PDUFA target date. The company is preparing for a pre-approval manufacturing inspection. - Azurity partnership provides funding and commercialization support:…This story appeared on finance.yahoo.com , 2026-08-12 16:04:30.